---
input_text: 'Acute hemodialysis therapy in neonates with inborn errors of metabolism.
  BACKGROUND: Inborn errors of metabolism (IEM), including organic acidemias and urea
  cycle defects, are characterized by systemic accumulation of toxic metabolites with
  deleterious effect on the developing brain. While hemodialysis (HD) is most efficient
  in clearing IEM-induced metabolic toxins, data regarding its use during the neonatal
  period is scarce. METHODS: We retrospectively summarize our experience with HD in
  20 neonates with IEM-induced metabolic intoxication (seven with maple syrup urine
  disease, 13 with primary hyperammonia), over a 16-year period, between 2004 and
  2020. All patients presented with IEM-induced neurologic deterioration at 48 h to
  14 days post-delivery, and were managed with HD in a pediatric intensive care setting.
  HD was performed through an internal jugular acute double-lumen catheter (6.5-7.0
  French), using an AK-200S (Gambro, Sweden) dialysis machine and tubing, with F3
  or FXpaed (Fresenius, Germany) dialyzers. RESULTS: Median (interquartile range)
  age and weight at presentation were 5 (3-8) days and 2830 (2725-3115) g, respectively.
  Two consecutive HD sessions decreased the mean leucine levels from 2281 +- 631 to
  179 +- 91 mumol/L (92.1% reduction) in MSUD patients, and the mean ammonia levels
  from 955 +- 444 to 129 +- 55 mumol/L (86.5% reduction), in patients with hyperammonemia.
  HD was uneventful in all patients, and led to marked clinical improvement in 17
  patients (85%). Three patients (15%) died during the neonatal period, and four died
  during long-term follow-up. CONCLUSIONS: Taken together, our results indicate that
  HD is safe, effective, and life-saving for most neonates with severe IEM-induced
  metabolic intoxication, when promptly performed by an experienced and multidisciplinary
  team. A higher resolution version of the Graphical abstract is available as Supplementary
  information.'
raw_completion_output: |-
  primary_disease: Inborn errors of metabolism (IEM)

  medical_actions: Hemodialysis (HD); Use of an internal jugular acute double-lumen catheter; Use of an AK-200S dialysis machine and tubing; Use of F3 or FXpaed dialyzers

  symptoms: Neurologic deterioration; Metabolic intoxication

  chemicals: Leucine; Ammonia

  action_annotation_relationships: Hemodialysis (HD) TREATS neurologic deterioration IN Inborn errors of metabolism (IEM); Hemodialysis (HD) TREATS metabolic intoxication IN Inborn errors of metabolism (IEM); Hemodialysis (HD) TREATS high leucine levels IN Inborn errors of metabolism (IEM); Hemodialysis (HD) TREATS high ammonia levels IN Inborn errors of metabolism (IEM)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Hemodialysis (HD) TREATS high ammonia levels IN Inborn errors of metabolism (IEM)

  ===

extracted_object:
  primary_disease: MONDO:0019052
  medical_actions:
    - MAXO:0000602
    - Use of an internal jugular acute double-lumen catheter
    - Use of an AK-200S dialysis machine and tubing
    - Use of F3 or FXpaed dialyzers
  symptoms:
    - HP:0002344
    - Metabolic intoxication
  chemicals:
    - CHEBI:25017
    - CHEBI:28938
  action_annotation_relationships:
    - subject: MAXO:0000602
      predicate: TREATS
      object: HP:0002344
      qualifier: MONDO:0019052
    - subject: MAXO:0000602
      predicate: TREATS
      object: metabolic intoxication
      qualifier: MONDO:0019052
    - subject: MAXO:0000602
      predicate: TREATS
      object: high leucine levels
      qualifier: MONDO:0019052
    - subject: MAXO:0000602
      predicate: TREATS
      object: high ammonia levels
      qualifier: MONDO:0019052
named_entities:
  - id: MONDO:0009563
    label: Maple syrup urine disease (MSUD)
  - id: CHEBI:25017
    label: Leucine
  - id: CHEBI:22359
    label: alloisoleucine (allo-ile)
  - id: HP:0100626
    label: End stage liver diseases
  - id: MONDO:0100193
    label: End stage liver diseases
  - id: MONDO:0019052
    label: Inborn errors of metabolism
  - id: MAXO:0000603
    label: Peritoneal dialysis
  - id: MAXO:0001175
    label: Liver transplantation (LT)
  - id: MAXO:0009003
    label: Preimplantation genetic testing (PGT)
  - id: CHEBI:24898
    label: isoleucine
  - id: CHEBI:27266
    label: valine
  - id: MAXO:0000088
    label: diet
  - id: HP:0001263
    label: mental and motor retardation
  - id: HP:0002098
    label: respiratory distress
  - id: MONDO:0008143
    label: Organic Acidemias (OAs)
  - id: MONDO:0000688
    label: Organic Acidemias
  - id: MONDO:0021055
    label: Familial amyloidotic polyneuropathy (FAP)
  - id: HP:0003159
    label: hyperoxaluria
  - id: MONDO:0002474
    label: primary hyperoxaluria
  - id: MONDO:0008294
    label: acute intermittent porphyria
  - id: HP:0011034
    label: Amyloidosis
  - id: HP:0011968
    label: Poor feeding
  - id: HP:0001259
    label: Coma
  - id: HP:0001252
    label: Hypotonia
  - id: HP:0002013
    label: vomiting
  - id: HP:0000737
    label: irritability
  - id: HP:0003256
    label: Coagulopathy
  - id: HP:0001993
    label: Ketoacidosis
  - id: HP:0001251
    label: Ataxia
  - id: MONDO:0017052
    label: intermediate maple syrup urine disease (iMSUD)
  - id: MAXO:0001525
    label: Intravenous administration
  - id: CHEBI:17895
    label: Tyr
  - id: CHEBI:16828
    label: Trp
  - id: CHEBI:141437
    label: His
  - id: CHEBI:16044
    label: Met
  - id: CHEBI:16857
    label: Thr
  - id: CHEBI:30011
    label: Gln
  - id: CHEBI:17295
    label: Phe
  - id: CHEBI:28300
    label: glutamine
  - id: CHEBI:16449
    label: alanine
  - id: CHEBI:27363
    label: zinc
  - id: CHEBI:27568
    label: selenium
  - id: CHEBI:27432
    label: alpha-linolenic acid (18:3n-3)
  - id: CHEBI:36005
    label: docosahexaenoic acid (22:6n-3)
  - id: CHEBI:17865
    label: Alpha-ketoisocaproate (KIC)
  - id: HP:0003811
    label: Neonatal death
  - id: HP:0001873
    label: thrombocytopenia
  - id: HP:0002615
    label: hypotension
  - id: HP:0002901
    label: hypocalcemia
  - id: HP:0001942
    label: metabolic acidosis
  - id: CHEBI:145810
    label: Insulin
  - id: MONDO:0008867
    label: biliary atresia
  - id: CHEBI:48430
    label: Alpha-ketoisocaproic acid (KIC)
  - id: MAXO:0000600
    label: renal replacement therapy (RRT)
  - id: MAXO:0000601
    label: dialysis
  - id: CHEBI:15603
    label: amino-acid mixture without leucine (Leu), valine, isoleucine
  - id: MAXO:0001495
    label: parenteral administration
  - id: MAXO:0000943
    label: Dried blood spot (DBS) monitoring
  - id: CHEBI:22918
    label: Branched-chain amino acids (BCAA)
  - id: CHEBI:33349
    label: <Dried blood spot (DBS)>
  - id: MONDO:0009949
    label: PC deficiency
  - id: HP:0001977
    label: abnormal blood clotting
  - id: HP:0000717
    label: Autism
  - id: HP:0001249
    label: Intellectual disability
  - id: HP:0001250
    label: Seizures
  - id: MONDO:0004739
    label: <Urea cycle defects (UCD), organic acidemias (OA), maple syrup urine disease
      (MSUD)>
  - id: HP:0001987
    label: elevated ammonia levels
  - id: CHEBI:29987
    label: Glutamate
  - id: CHEBI:21547
    label: N-acetylaspartate (NAA)
  - id: CHEBI:16919
    label: Creatine
  - id: HP:0006846
    label: acute encephalopathy
  - id: HP:0033667
    label: mental impairment (IQ <= 70)
  - id: HP:0001943
    label: Hypoglycemia
  - id: HP:0001257
    label: Spasticity
  - id: HP:0000988
    label: Rash
  - id: HP:0001876
    label: Pancytopenia
  - id: HP:0001919
    label: Acute kidney injury
  - id: HP:0030005
    label: Capillary leak syndrome
  - id: CHEBI:176838
    label: Riboflavin (vitamin B2)
  - id: CHEBI:176841
    label: Biotin (vitamin B7)
  - id: HP:0002878
    label: respiratory failure
  - id: HP:0010911
    label: Hyperleucinemia
  - id: MAXO:0001001
    label: gene therapy
  - id: HP:0000938
    label: osteopenia
  - id: CHEBI:28938
    label: ammonia
  - id: CHEBI:30860
    label: methylmalonic acid
  - id: CHEBI:15702
    label: Tissue plasminogen activator (tPA)
  - id: HP:0001699
    label: sudden death
  - id: MAXO:0000932
    label: Electroencephalography
  - id: HP:0001298
    label: Encephalopathy
  - id: HP:0002586
    label: peritonitis
  - id: HP:0003774
    label: chronic renal failure
  - id: MONDO:0008723
    label: Very-long chain acyl-CoA dehydrogenase deficiency (VLCAD)
  - id: CHEBI:17453
    label: methylmalonate
  - id: MONDO:0002012
    label: Methylmalonic Acidemia
  - id: MONDO:0008815
    label: Argininosuccinic Aciduria (ASA)
  - id: MAXO:0000602
    label: Hemodialysis (HD)
  - id: HP:0002344
    label: Neurologic deterioration
